Loading
A phase 1/2 trial of E-EDV-D682, Gemcitabine, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Engeneic Pty Limited, now recruiting.
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer is a phase 1/2 interventional study registered as NCT07049055 by Engeneic Pty Limited, with 144 participants planned, started 2026-01-12 and due to reach its primary completion in 2028-09. Interventions recorded: E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel.. Conditions listed: Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/